Cargando…
Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second most common cause of death due to cancer. About 30% of patients with PCa who have been castrated develop a castration-resistant form of the disease (CRPC), which is incurable. In the last decade, new treatments that control t...
Autores principales: | Hawlina, Simon, Zorec, Robert, Chowdhury, Helena H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382052/ https://www.ncbi.nlm.nih.gov/pubmed/37511873 http://dx.doi.org/10.3390/life13071498 |
Ejemplares similares
-
Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number
por: Hawlina, Simon, et al.
Publicado: (2022) -
Survival of castration‐resistant prostate cancer patients treated with dendritic–tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56(bright)CD16(−) natural killer cells
por: Haque Chowdhury, Helena, et al.
Publicado: (2021) -
Exocytotic fusion pore under stress
por: Chowdhury, Helena Haque, et al.
Publicado: (2020) -
Insulin Induces an Increase in Cytosolic Glucose Levels in 3T3-L1 Cells with Inhibited Glycogen Synthase Activation
por: Chowdhury, Helena H., et al.
Publicado: (2014) -
Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell–Based Vaccine in Prostate Cancer–Bearing Mice
por: Wei, Si-Ming, et al.
Publicado: (2015)